All In Biotech

Drug Trial Radar · NCT05714514

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys

A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Apr 21, 2023

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Feb 6, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).

Conditions

  • Kidney Transplantation in Highly Sensitized Patients

Interventions

  • Imlifidase administered in the ConfIdeS studyDrug

    Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.

  • Best available treatment administered in the ConfIdeS studyOther

    Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients alive and free of dialysis at 3 yearsTime frame: 3 years after randomization in the ConfIdeS study

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (UAB) Hospital

    Birmingham, Alabama

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Northwestern University, Dept. General Surgery, Div. Transplantation

    Chicago, Illinois

  • University of Chicago, Department of Surgery, Clinical Research Center

    Chicago, Illinois

  • John Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Cooperman Barnabas Medical Center

    Livingston, New Jersey

  • New York University (NYU) Langone Transplant Institute, NYU Langone Health

    New York, New York

  • Columbia University

    New York, New York

  • Houston Methodist Hospital

    Houston, Texas

  • Methodist Hospital Specialty and Transplant

    San Antonio, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.